Literature DB >> 29131458

Image analysis is an excellent tool for quantifying Ki-67 to predict the prognosis of gastrointestinal stromal tumor patients.

Shintaro Sugita1, Hiroshi Hirano1, Yutaka Hatanaka2, Hiromi Fujita1, Terufumi Kubo1, Noriaki Kikuchi1, Yumika Ito1, Taro Sugawara1, Keiko Segawa1, Hiroyuki Hisai3, Kentaro Yamashita4, Takayuki Nobuoka5, Yoshihiro Matsuno2, Tadashi Hasegawa1.   

Abstract

We investigated the quantification of Ki-67 staining using digital image analysis (IA) as a complementary prognostic factor to the modified National Institutes of Health (NIH) classification in patients with gastrointestinal stromal tumor (GIST). We examined 92 patients, focusing on the correlation between age, sex, primary tumor site, tumor size, predominant histologic type, mitotic index, modified NIH classification (low/intermediate vs high), Ki-67 quantitation, and recurrence-free survival (RFS). We compared two IA processes for whole slide imaging (WSI) and manually captured image (MCI) methods. A Ki-67 quantitation cutoff was determined by receiver operator characteristics curve analysis. In the survival analysis, the high-risk group of a modified NIH classification, a mitotic count >5 per 20 high-powered fields, and Ki-67 cutoffs of ≥6% and ≥8% obtained by IA of the WSI and MCI methods, respectively, had an adverse impact on RFS. On multivariate analysis, each Ki-67 quantitation method strongly predicted prognosis, more strongly than the modified NIH classification. In addition, Ki-67 quantitation using IA of the MCI method could stratify low or intermediate risk and high risk GIST patients. Thus, IA is an excellent tool for quantifying Ki-67 to predict the prognosis of GIST patients, and this semiautomated approach may be preferable for patient care.
© 2017 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Ki-67; gastrointestinal stromal tumor; image analysis; prognostic factor; quantitation

Mesh:

Substances:

Year:  2017        PMID: 29131458     DOI: 10.1111/pin.12611

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  Surgical treatment of gastrointestinal stromal tumours combined with imatinib treatment: a retrospective cohort analysis.

Authors:  Robert Bachmann; Jens Strohäker; Julian Kraume; Alfred Königsrainer; Ruth Ladurner
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-27

2.  Ki-67 Proliferation Index Assessment in Gastroenteropancreatic Neuroendocrine Tumors by Digital Image Analysis With Stringent Case and Hotspot Level Concordance Requirements.

Authors:  Sarag A Boukhar; Matthew D Gosse; Andrew M Bellizzi; Anand Rajan K D
Journal:  Am J Clin Pathol       Date:  2021-09-08       Impact factor: 2.493

3.  CT Radiomics for the Preoperative Prediction of Ki67 Index in Gastrointestinal Stromal Tumors: A Multi-Center Study.

Authors:  Yilei Zhao; Meibao Feng; Minhong Wang; Liang Zhang; Meirong Li; Chencui Huang
Journal:  Front Oncol       Date:  2021-09-14       Impact factor: 6.244

4.  Tumor Digital Masking Allows Precise Patient Triaging: A Study Based on Ki-67 Scoring in Gastrointestinal Stromal Tumors.

Authors:  Piotr Lewitowicz; Jaroslaw Matykiewicz; Magdalena Chrapek; Dorota Koziel; Agata Horecka-Lewitowicz; Martyna Gluszek-Osuch; Iwona Wawrzycka; Stanisław Gluszek
Journal:  Scanning       Date:  2018-09-02       Impact factor: 1.932

5.  Prognostic usefulness of a modified risk model for solitary fibrous tumor that includes the Ki-67 labeling index.

Authors:  Shintaro Sugita; Keiko Segawa; Noriaki Kikuchi; Tomoko Takenami; Tomomi Kido; Makoto Emori; Yukinori Akiyama; Kohichi Takada; Shiro Hinotsu; Tadashi Hasegawa
Journal:  World J Surg Oncol       Date:  2022-02-01       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.